Navigation Links
QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Date:7/26/2010

S studies was considered acceptable for MAA submission in Europe with the addition of a Phase 3 study in bunionectomy patients comparing the adverse event profile of MoxDuo IR to equianalgesic doses of morphine and of oxycodone (total n=300). This study will include the proposed primary safety endpoints of the occurrence rate of moderate-severe nausea, emesis or dizziness, with an improvement for MoxDuo IR compared to morphine and oxycodone treatments being defined as a clinically relevant effect.

Assuming a positive outcome of this additional study and pending review of the MAA, such differences may be cited in the product package labelling in Europe and will further augment data for label claim submission with the FDA in the US.

QRxPharma successfully completed a pivotal Phase 3 "combination rule" study in April 2010 and announced that primary and secondary endpoints were achieved. In this study, MoxDuo IR 2 demonstrated both a statistically superior analgesic effect compared to morphine and oxycodone alone as well as a favourable side effect profile despite delivering twice the opioid dose of its individual components. These findings complement earlier clinical trials demonstrating that MoxDuo IR opens the therapeutic window by providing significant acute pain relief while reducing side effects.

About Scientific Advice:

The Scientific Advice process provides QRxPharma a forum to discuss the adequacy of its MoxDuo IR development plan as well as the results obtained to date for product registration purposes. The responses given by the Agencies are based on the questions and documentation submitted for discussion and cannot account for future changes or developments in scientific knowledge or regulatory requirements. Scientific Advice given i
'/>"/>

SOURCE QRXPharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... October 19, 2014 Große ... Das Problem dabei ist, dass große Pharmafirmen ... Kompetenz zu teilen. Es war deshalb ... wir uns umso mehr, dass es uns gelungen ... bei Kühlketten aufzuschreiben - mit einem Vorbehalt - ...
(Date:10/17/2014)... , Oct. 17, 2014  Training market ... a critical success factor in today,s highly competitive ... market research organizations that effectively and efficiently produce ... or service area. Effective training ... and earn recognition from internal clients by developing ...
(Date:10/17/2014)... , Oct. 17, 2014 UBM Medica US ... a leading online community and information resource for neurologists and ... and Alzheimer disease , with discussions of the ... 1 million Americans have Parkinson disease , more than ... or Lou Gehrig disease. Diagnosis can be difficult ...
Breaking Medicine Technology:Vergleichsbericht zu Pharma-Kühlketten und CRT 2Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3
... An optimized PARI eFlow,platform nebulizer will be ... trial that has begun enrolling patients. ALN-RSV01 is ... respiratory syncytial virus,(RSV) infection, the leading cause of ... in immune-compromised adults. RSV currently does,not have a ...
... SGP ), a leader in advancing the ... infection, announced today that final,results of the IDEAL ... studies,with PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP),combination ... for the,Study of the Liver (EASL) 43rd annual ...
Cached Medicine Technology:PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 7Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 8Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 9
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The ... member hospital ROI on membership dues at 12.5. In other ... $12.50 in value to member hospitals. The calculation used to ... Dues. , “This is the first time we’ve actually ... the methodology is really sound,” said Bill Ryan , ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher ... of his innovative True Form Tummy Tuck® ... and faculty at The University of Texas Medical ... once a medical student. Patronella, who is a founding ... surgery practices in Texas, The Aesthetic Center for ...
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, ... and GreenGeeks are the best Dedicated Server Hosting ... who want to buy high quality hosting and ... IT manager of Top10BestSEOHosting.com says, “We believe that ... for everyone. A lot of the global clients ...
(Date:10/19/2014)... October 20, 2014 This report ... Partial Seizure, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ... and press releases. It also reviews key players ... and special features on late-stage and discontinued projects. ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides many ... latest designs of 2014 mother of the bride ... are offered with big discounts, up to 70% off. ... can enjoy this special offer. , Owing to ... become one of the leading brands in the global ...
Breaking Medicine News(10 mins):Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2
... Citing persistent noncompliance and numerous performance deficiencies, the Department of ... a five-year, $75 million contract with the University of Texas ... Veterans, Illnesses (GWVI). , , "Research into ... for VA," said Dr. Gerald M. Cross, VA,s Acting Under ...
... , , , ... WASHINGTON, Aug. 26 Last night in northern Virginia, Representative James ... health care that was attended by thousands of people. Anti-abortion extremist ... the event that he would be there to disrupt it by ...
... Breast Cancer Metastasis Dr. Amanda Harvey and colleagues ... a role in breast cancer progression and dissemination. Their ... the American Journal of Pathology . ... breast cancer patients. Non-metastatic breast cancer cells rely on ...
... Singapore are reporting development of a new electronic sensor that ... alternative than tests now used to detect DNA. Such ... purposes. The new lab-on-a-chip test could lead to wider, more ... is scheduled for the Sept. 2 issue of the ...
... , Large variations exist in peoples, ability to eliminate arsenic ... existing standards for evaluating the human health risks from the ... more than 90 percent of the arsenic consumed in the ... have harmful effects. The research, based on the first application ...
... , PALM BEACH GARDENS, Fla., Aug. 26 The only effective ... from Chinese Drywall is now available. The RISS System(TM) removes the ... RISS system is so unique that it is in Patent Pending status with ... The RISS System(TM) : ( www.RISS s y s ...
Cached Medicine News:Health News:VA Continues Gulf War Research, Cancels Contract with UTSW Medical Center 2Health News:Randall Terry Removed By Police From Howard Dean Health Care Town Hall Meeting 2Health News:Tips from the American Journal of Pathology 2Health News:Tips from the American Journal of Pathology 3Health News:Tips from the American Journal of Pathology 4Health News:Tips from the American Journal of Pathology 5Health News:Proven Solution for Chinese Drywall is Now Available 2
... LactoSorb copolymer maintains almost all its mechanical ... mass loss in 915 months. Blunt thread ... Seventeen sizes to maximize surgeons options. ... entire screw to help prevent the screw ...
... The Asnis III™ Cannulated Screw System ... 2 and TCS Systems and combined them ... cannulated screws in both titanium and stainless ... Screw System is designed to optimize surgical ...
The properties of titanium alloy have been combined with a uniquely designed reverse radial tapping flute to produce a state-of-the-art fracture fixation system....
... The VersaNail System is a complete system ... to use with TTC fusion surgery. The ... specialists and integrates clinical research and engineering ... Because every patient is different, and because ...
Medicine Products: